Showing 661-670 of 2366 results for "".
Pay for Performance: Understanding and Preparing for MIPS
https://practicalneurology.com/columns/practice-management/pay-for-performance-understanding-and-preparing-for-mips/30418/As a new reimbursement model is set to unveil, physicians will have a tight window to prepare their practices to begin reporting in 2017.Update on Refractory Status Epilepticus
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/update-on-refractory-status-epilepticus/30758/The first priority for the consulting neurologist is confirming the diagnosis. Treating any underlying disease does far more to improve outcome than mere suppression of seizures. Treatment options exist for prolonged SE, but clinicians must be realistic with families.Onabotulinumtoxin A for Headache: An Update
https://practicalneurology.com/diseases-diagnoses/headache-pain/onabotulinumtoxin-a-for-headache-an-update/30783/A year after FDA approval, a specialist offers an update on neurotoxin therapy for migraine and headache.Hemicrania Continua: A Question and Answer Review
https://practicalneurology.com/diseases-diagnoses/headache-pain/hemicrania-continua-a-question-and-answer-review/30785/A headache specialist explores the incidence, diagnosis, and treatment of this frequently misdiagnosed headache type.Spinal Cord Infarct: Clinical & Imaging Pearls
https://practicalneurology.com/diseases-diagnoses/imaging-testing/spinal-cord-infarct-clinical--imaging-pearls/30394/Rising Drug Prices and the Cost of Care: What Can Physicians Do?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/rising-drug-prices-and-the-cost-of-care-what-can-physicians-do/30327/The multiple sclerosis drug market offers a snapshot of a growing problem. Physicians should speak out on behalf of the specialty and their patients.Preferred Treatment: The Changing Economics of Multiple Sclerosis Care
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/preferred-treatment-the-changing-economics-of-multiple-sclerosis-care/30486/By deciding which drugs are “preferred,” insurance companies are reducing the practice of evidence-based medicine to a series of economic choices.NeuroAdvocacy: Why Lobbying Matters
https://practicalneurology.com/columns/practice-management/neuroadvocacy-why-lobbying-matters/30328/Advocating for patients and the specialty is a powerful way for physicians to make their voices heard.Confronting the Clinical Challenges of Frontotemporal Dementia
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/confronting-the-clinical-challenges-of-frontotemporal-dementia/30848/A look at FTD's symptoms, pathophysiology, subtypes, as well as the latest from imaging studies.Filling the Gap in Pediatric Neurology
https://practicalneurology.com/diseases-diagnoses/child-neurology/filling-the-gap-in-pediatric-neurology/30265/The view from an area without pediatric neurologists.